Pure Biologics

Pure Biologics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pure Biologics (PUR.WA) as of Nov 17, 2026 is 63.93 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 55.72 % — a change of 14.74% (higher).

FCF Conversion

63.93 %

YoY

14.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pure Biologics is 2025 63.93 % . FCF Conversion Rate (FCF/EBITDA) of Pure Biologics was 2024 55.72 % . It decreases by 14.74% higher compared to the previous year.

The Pure Biologics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
384.43 PLN
Jan 1, 2019
-109.95 PLN
Jan 1, 2020
15.81 PLN
Jan 1, 2021
189.03 PLN
Jan 1, 2022
87.76 PLN
Jan 1, 2023
65.66 PLN
Jan 1, 2024
55.72 PLN
Jan 1, 2025
63.93 PLN
The Pure Biologics FCF Conversion history
YEARFCF ConversionYoY
63.93 %+14.74%
55.72 %-15.14%
65.66 %-25.18%
87.76 %-53.57%
189.03 %+1,095.51%
15.81 %-114.38%
-109.95 %-128.60%
384.43 %-47.31%
729.65 %+174.27%
266.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

FCF Conversion Rate (FCF/EBITDA) of Pure Biologics is 63.93 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Pure Biologics changed from 55.72 % to 63.93 %, representing a 14.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pure Biologics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Pure Biologics

All Key Metrics — Pure Biologics